The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Antibodies sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Antibodies is a provider of immunochemistry products and services. Its products portfolio includes primary antibody, secondary antibody, normal sara, in-vitro diagnostic kit, blocking reagent, immunoprecipitation reagent. It offers services such as contract manufacturing, antibody development hybridoma mab scale-up, antibody conjugation, antibody purification, ELISA, immunoassay, biospecimen storage and animal housing services. The company operates through laboratories, manufacturing, and animal care units.It operates its business under brand name such as neuromab, antibodies incorporated, aves labs, and phosphosolutions. It markets immunochemistry products through a network of distributors across Europe, Asia, and North America. Antibodies is headquartered in Davis, California, the US.
The key metrics of Antibodies related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As Antibodies is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Antibodies.
For a detailed understanding of the performance of Antibodies, buy the report here.